Once‐weekly (70 mg/m(2)) vs twice‐weekly (56 mg/m(2)) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION‐1 trials

Podobne knjige/članki

• Once- versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma by select patient characteristics: phase 3 A.R.R.O.W. study subgroup analysis
  od: Dimopoulos, Meletios A., et al.
  Izdano: (2020)
• Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR
  od: Dimopoulos, Meletios, et al.
  Izdano: (2019)
• Once-weekly vs. twice-weekly carfilzomib dosing in a subgroup of Japanese relapsed and refractory multiple myeloma patients from a randomized phase 3 trial (A.R.R.O.W.) and comparison with ENDEAVOR
  od: Takezako, Naoki, et al.
  Izdano: (2020)
• Weekly carfilzomib, lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: A phase 1b study
  od: Biran, Noa, et al.
  Izdano: (2019)
• A phase 1b study of once‐weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma
  od: Alsina, Melissa, et al.
  Izdano: (2020)